Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
*Corresponding author: Atthaphorn Trakarnsanga E-mail: atthaphornt@gmail.com
Received 18 February 2026 Revised 4 May 2026 Accepted 4 May 2026 ORCID ID: http://orcid.org/0000-0002-1980-7782 https://doi.org/10.33192/smj.v78i7.280490
All material is licensed under terms of the Creative Commons Attribution 4.0 International (CC-BY-NC-ND 4.0) license unless otherwise stated.
ABSTRACT
Results: A total of 979 patients (median age: 65 years) were included. Of those, 18.4% had stage I, 38.6% had stage II, and 43.0% had stage III disease. The calculated median DIT of 30 days (IQR: 19-47) was used as the cutoff value to categorize patients into the ≤30-days or >30-days group. The 5-year overall survival rate was 97.6% and 97.1% (p=0.536), and the median survival time was 59.4 and 58.9 months - both respectively. The 3-year disease-free survival (DFS) rate was 86.9% and 85.7%, respectively (p=0.523). The independent predictors of decreased 3-year DFS among all patients were lymph node metastasis (p=0.037), adjuvant chemotherapy (p=0.005), and lymphovascular invasion (p=0.051). Further multivariate analysis in the DIT >30-days group found low preoperative albumin level (p=0.035), perineural invasion (p=0.011), and adjuvant chemotherapy (p<0.001) to independently predict significantly poorer 3-year DFS.
INTRODUCTION
Colorectal cancer (CRC) is currently ranked as the third most prevalent cancer in Thai men, and the fourth most prevalent cancer in Thai women, based on data from the Thailand National Cancer Institute covering the years 2013 to 2015. The incidence of CRC resulted in 17,534 newly diagnosed cases, comprising 10.3% of all newly diagnosed cancer cases during the same period. The incidence rate of CRC among Thai men was estimated to be 16.2 new cases per 100,000 Thai men, and the incidence rate of CRC among Thai women was estimated to be 11.2 new cases per 100,000 Thai women.1
The primary treatment for CRC is surgical intervention2, and delays in surgical intervention can lead to disease progression. Factors reported to be associated with delayed surgery include low educational attainment, small tumor size, and asymptomatic presentation at diagnosis.3 In Thailand, more than 25% of CRC patients experience surgical delays exceeding one month despite national guidelines recommending surgery within four weeks following clinical or radiological staging. This recommendation is part of the Thailand Ministry of Public Health’s Cancer Service Plan, which sets a 28-day benchmark as a key performance indicator for timely access to care. For our analysis, the 30-day cutoff was determined post hoc
based on the median diagnosis-to-surgery interval time (DIT) of our patient cohort. This data-driven threshold was utilized to ensure a balanced statistical comparison, while also holding clinical significance as it closely aligns with the 28-day national standard.4
The relationship between the diagnosis-to-surgery interval time (DIT) and survival rates has yielded inconclusive findings in previous studies. While some studies have failed to establish a correlation between time and survival rates5-11, others have identified a negative correlation between longer wait times and lower survival rates.12,13 Moreover, a few studies have reported a U-shaped relationship between the duration and survival rates.14-16 However, no studies on this topic have been conducted in Thailand.
This study aims to examine the factors affecting DIT and its impact on survival rates. The findings of this study can be applied to treatment planning and serve as a valuable source of information to enhance the healthcare system.
MATERIALS AND METHODS
This retrospective cohort study included adult patients with stage I–III CRC who underwent elective surgery at Siriraj Hospital, Thailand, from January 2010 to December 2020. DIT was calculated from the date the
pathological report was issued to the date of definitive surgery. This specific point was chosen as it reflects the practical onset of definitive surgical decision-making and scheduling. We excluded patients with a second primary cancer, emergency conditions (e.g., bowel obstruction or perforation), or who received neoadjuvant chemoradiation, or had tumors in the middle or lower rectum (≤10 cm from the anal verge). Emergency cases were excluded because they typically undergo urgent surgery, have poorer prognosis, and shorter DITs, which could bias survival estimates in the short DIT group. Middle and lower rectal tumors were excluded due to the high likelihood of neoadjuvant therapy, which could confound the impact of DIT.2 To minimize confounding and improve comparability, we included only patients with nonmetastatic colon and upper rectal cancer. The data employed in this research were extracted from the SIIT Enterprise patient database, the Ecliar laboratory test result database, and the E-portfolio surgical database. The study was approved by Siriraj Institutional Review Board, SIRB Protocol No. 058/2564 (IRB3).
The primary outcome of this study was to demonstrate an association between the 30-day cut-off DIT and survival for non-metastatic CRC. The secondary outcome was to identify risk factors associated with disease free survival for non-metastatic CRC.
A descriptive analysis using either mean and standard deviation or median and range based on the distribution of data. The study reported the 5-year overall survival (OS) rate and 3-year disease-free survival (DFS) rate, the Kaplan-Meier method was used. The log-rank test was used to compare the survival time of patients who underwent surgery for CRC within less than 30 days after diagnosis with those who underwent surgery after 30 days. Simple Cox regression analysis was used to explore the association with various factors such as comorbidities, cancer stage, cancer location, and surgical method. Multiple Cox regression analysis was conducted to adjust for significant independent factors from the analysis of simple Cox regression and survival time. Adjusted hazard ratios (HRs) were calculated to signify the magnitude and direction of the relationship between independent factors and survival time. Data was recorded and analyzed using IBM SPSS Statistics 21.0. with a p-value
< 0.05 considered statistically significant for all analyses.
RESULTS
A total of 979 patients (526 male, 53.7%) were included with a median age of 65 (IQR 57-74). Median DIT was 30 days (IQR 19-47). The DIT for non-metastatic CRC in this study were divided into two groups: ≤ 30 days
and > 30 days. Four hundred ninety-six patients (50.7%) patients received surgery within 30 days after diagnosis. Demographics of both groups were displayed in Table 1. In DIT within 30 days group, age, Charlson Comorbidity Index (CCI), American Society of Anesthesiologists (ASA) Classification and depth of invasion were significantly higher than another group.
The 5-year OS was 96.1% and 3-year DFS was 84.6%. Among patients who underwent surgery within 30 days of diagnosis, the 5-year OS was 97.6%, compared to 97.1% in those with DIT >30 days. Similarly, the 3-year DFS was 86.9% in the ≤30 days group and 85.7% in the
>30 days group, respectively. Delayed DIT > 30 days was not associated with 5-year OS (p value 0.536) and 3-year DFS (p value 0.523). The survival curves were demonstrated in Fig 1 and 2.
Risk factors of 3-year DFS in non-metastatic CRC were displayed in Table 2. The independent risk factors were higher preoperative carcinoembryonic antigen (CEA) level (HR 2.206; 95%CI 1.500-3.243), lower preoperative albumin level (HR 0.662; 95%CI 0.484-0.906), lymph node metastasis (HR 3.492; 95%CI 2.418-5.043), presence of perineural invasion (PNI) (HR 2.597; 95%CI 1.845-3.656), presence of lymphovascular invasion (LVI) (HR 2.144; 95%CI 1.504-3.055) and received adjuvant chemotherapy (HR 6.601; 95%CI 3.969-10.980), which serves as a surrogate marker for high-risk disease (Stage II/III). In addition, lymph node metastasis and received adjuvant chemotherapy were independent factors of 3-year DFS.
In the subgroup analysis of patients with a DIT within 30 days, clinical parameters were significantly associated with a 3-year DFS, as displayed in Table 3. Notably, higher preoperative CEA levels (HR 2.333; 95%CI 1.327-4.103), lymph node metastasis (HR 2.411; 95%CI 1.450-4.008), the presence of PNI (HR 1.809; 95%CI 1.102-2.971), the presence of LVI (HR 2.387; 95%CI 1.438-3.962) and receiving adjuvant chemotherapy (HR 4.585; 95%CI 2.268-9.269) were identified as dependent factors of the 3-year DFS. However, multivariate analysis revealed that only higher preoperative CEA levels (HR 2.146; 95%CI 1.218-3.780) and receiving adjuvant chemotherapy (HR 3.825; 95%CI 1.863-7.855) remained as independent factors.
In another group of patients with a DIT more than 30 days, clinical factors were associated with 3-year DFS, as displayed in Table 4. Specifically, higher preoperative CEA levels, lower preoperative albumin levels, laparoscopic surgery, lymph node metastasis, the presence of PNI, the presence of LVI, and receiving adjuvant chemotherapy were identified as dependent factors. However, multivariate
TABLE 1. Patient demographic and clinical characteristics among all patients, and compared between the DIT
≤30 days and >30 days groups.
Patient characteristics Overall patients DIT ≤30 days DIT >30 days p-value | ||||
(n=979) | (n=496) | (n=483) | ||
Age (years), median [IQR] | 65 [57-74] | 65 [56-74] | 67 [58-75] | 0.003 |
Male sex, n (%) | 526 (53.7%) | 270 (54.4%) | 256 (53.0%) | 0.700 |
Body mass index, median [IQR] | 23.4 [20.6-25.6] | 23.2 [20.5-25.5] | 23.6 [20.8-25.8] | 0.159 |
Charleson Comorbidity Index, mean±SD | 5.85±1.953 | 5.65±1.914 | 6.05±1.974 | 0.002 |
ASA classification, n (%) Class I | 242 (24.7%) | 147 (29.6%) | 95 (19.7%) | 0.001 |
Class II | 507 (51.8%) | 247 (49.8%) | 260 (53.8%) | |
Class III | 230 (23.5%) | 102 (20.6%) | 128 (26.5%) | |
Preoperative CEA level (ng/mL), | 3.91 [2.21-8.69 | 3.91 [2.12-9.22] | 3.87 [2.24-8.28] | 0.814 |
median [IQR] | ||||
Preoperative albumin level (g/dL), median [IQR] | 4.1 [3.8-4.4] | 4.1 [3.8-4.4] | 4.1 [3.8-4.3] | 0.236 |
DIT (days), median [IQR] | 30 [19-47] | |||
Type of surgery, n (%) Open | 482 (49.2%) | 242 (48.8%) | 240 (49.7%) | 0.828 |
Laparoscopic | 497 (50.8%) | 254 (51.2%) | 243 (50.3%) | |
Conversion, n (%) | 20 (4.0%) | 10 (3.9%) | 10 (4.1%) | 1.000 |
Depth of invasion, n (%) T1 | 102 (10.4%) | 12 (4.7%) | 47 (19.3%) | <0.001 |
T2 | 146 (14.9%) | 38 (15.0%) | 44 (18.1%) | |
T3 | 615 (62.8%) | 176 (69.3%) | 135 (55.6%) | |
T4 | 116 (11.8%) | 28 (11.0%) | 17 (7.0%) | |
Lymph nodes collected (n), median [IQR] | 20 [15-28] | 19 [15-26] | 19 [15-29] | 0.047 |
Lymph node status, n (%) 0 | 572 (58.5%) | 142 (55.9%) | 151 (62.1%) | 0.286 |
1-3 | 283 (28.9%) | 84 (33.1%) | 67 (27.6%) | |
≥4 | 123 (12.6%) | 28 (11.0%) | 25 (10.3%) | |
Grade, n (%) Well-differentiated | 72 (7.4%) | 14 (5.5%) | 25 (10.3%) | 0.365 |
Moderately-differentiated | 852 (87.1%) | 226 (89.0%) | 208 (86.0%) | |
Poorly-differentiated | 15 (1.5%) | 2 (0.8%) | 1 (0.4%) | |
Undifferentiated/anaplastic | 39 (4.0%) | 12 (4.7%) | 8 (3.3%) | |
Presence of PNI, n (%) | 260 (26.9%) | 72 (28.3%) | 52 (21.4%) | 0.253 |
Presence of LVI, n (%) | 220 (22.6%) | 59 (23.2%) | 51 (21.0%) | 0.700 |
Positive margin, n (%) | 15 (1.5%) | 4 (1.6%) | 5 (2.1%) | 0.958 |
TABLE 1. Patient demographic and clinical characteristics among all patients, and compared between the DIT
≤30 days and >30 days groups. (Continued)
Patient characteristics | Overall patients (n=979) | DIT ≤30 days (n=496) | DIT >30 days (n=483) | p-value |
Location, n (%) | 0.491 | |||
Right-side colon | 228 (23.3%) | 60 (23.6%) | 57 (23.5%) | |
Left-side colon | 127 (13.0%) | 33 (13.0%) | 31 (12.8%) | |
Sigmoid colon | 504 (51.5%) | 136 (53.5%) | 121 (49.8%) | |
Upper rectum | 95 (9.7%) | 21 (8.3%) | 28 (11.5%) | |
Synchronous lesion | 25 (2.5%) | 4 (1.6%) | 6 (2.5%) | |
Adjuvant chemotherapy | 519 (53.0%) | 151 (59.4%) | 114 (46.9%) | <0.001 |
AJCC stage, n (%) | <0.001 | |||
I | 180 (18.4%) | 33 (13.0%) | 71 (29.2%) | |
II | 378 (38.6%) | 108 (42.5%) | 79 (32.5%) | |
III | 421 (43.0%) | 113 (44.5%) | 93 (38.3%) |
A p-value<0.05 indicates statistical significance
Abbreviations: AJCC, American Joint Committee on Cancer; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; DIT, diagnosis-to-surgery interval time; g/dL, grams per deciliter; IQR, interquartile range; LVI, lymphovascular invasion; n, number; ng/ mL, nanograms per milliliter; PNI, perineural invasion; p-value, probability value; SD, standard deviation; T, tumor
Fig 1. Kaplan-Meier survival analysis to determine the 5-year overall survival rate compared between the DIT ≤30-days group and the DIT
>30-days group (p=0.536).
Fig 2. Kaplan-Meier survival analysis to determine the 3-year disease-free survival rate compared between the DIT ≤30-days group and the DIT >30-days group (p=0.523).
analysis revealed that only higher preoperative albumin levels (hazard ratio [HR]: 0.611; 95% confidence interval [CI]: 0.387-0.965) remained as an independent protective factor, while the presence of PNI (HR: 1.904; 95%CI: 1.160-3.124) and receiving adjuvant chemotherapy (HR: 5.444; 95%CI: 2.178-13.606) were the only independent risk factors.
DISCUSSION
This retrospective cohort study evaluated the prognostic impact of DIT on oncological outcomes in patients with non-metastatic CRC undergoing curative resection. Our analysis demonstrated favorable long-term survival outcomes with 5-year OS of 96.1% and 3-year DFS of 84.6%. Notably, DIT exceeding 30 days did not demonstrate a statistically significant association with either 5-year OS or 3-year DFS. Subgroup analysis identified several clinicopathological variables associated with impaired 3-year DFS in patients with prolonged DIT (>30 days), including hypoalbuminemia, nodal metastases, perineural invasion, and receipt of adjuvant chemotherapy. However, multivariate Cox regression analysis confirmed that DIT >30 days did not retain statistical significance as an independent predictor of survival outcomes, while hypoalbuminemia, perineural invasion, and adjuvant chemotherapy administration
remained independent prognostic factors for 3-year DFS. Importantly, to prevent misinterpretation, it is crucial to note that adjuvant chemotherapy administration acts as a surrogate marker for high-risk disease characteristics—such as advanced stage (Stage II/III) or aggressive tumor biology—rather than being the underlying cause of decreased survival.
The absence of significant association between 30-day surgical delay and survival outcomes can be explained by established tumor biology principles and Gompertzian growth dynamics. Colorectal adenocarcinomas typically exhibit Gompertzian growth kinetics, characterized by exponential proliferation during early carcinogenesis followed by growth deceleration as tumor volume increases and nutrient supply becomes limiting.17 Since DIT represents the interval following clinical detection, when tumors have already achieved substantial size and entered the plateau phase of growth, brief delays of 30 days are unlikely to significantly alter tumor burden or metastatic potential. This biological rationale supports our finding that moderate DIT thresholds may not independently influence long-term oncological outcomes in non-metastatic colorectal carcinoma.
Our findings are consistent with modeling studies that demonstrate the critical distinction between moderate and prolonged surgical delays. Sud et al. projected that
TABLE 2. Multivariate analysis for independent predictors of decreased 3-year DFS among all Thai non-metastatic colorectal cancer patients included in this study.
Factors | HR (95%CI) | p-value | aHR (95%CI) | p-value | |
Age | 1.002 (0.990-1.019) | 0.568 | |||
Male sex | 1.058 (0.753-1.488) | 0.744 | |||
Body mass index | 0.977 (0.935-1.021) | 0.300 | |||
Charleson Comorbidity Index | 1.024 (0.939-1.118) | 0.588 | |||
ASA classification Class I | Reference | ||||
Class II | 1.101 (0.713-1.699) | 0.664 | |||
Class III | 1.362 (0.835-2.222) | 0.215 | |||
Preoperative CEA level >3.4 | 2.206 (1.500-3.243) | <0.001 | 1.164 (0.638-2.123) | 0.621 | |
Low preoperative albumin level | 0.662 (0.484-0.906) | 0.010 | 0.586 (0.321-1.070) | 0.082 | |
Delayed DIT >30 days | 1.003 (0.999-1.007) | 0.150 | |||
Laparoscopic surgery | 0.709 (0.504-0.999) | 0.049 | NA | NA | |
Conversion | 2.658 (1.057-6.685) | 0.038 | 1.804 (0.637-5.109) | 0.267 | |
Depth of invasion T1 | Reference | ||||
T2 | NA | NA | |||
T3 | NA | NA | |||
T4 | NA | NA | |||
Lymph node metastasis | 3.492 (2.418-5.043) | <0.001 | 2.252 (1.052-4.820) | 0.037 | |
Lymph node harvested <12 nodes | 1.081 (0.550-2.127) | 0.821 | |||
Grade Well-differentiated | Reference | ||||
Moderately-differentiated | 2.203 (0.900-5.390) | 0.084 | 0.554 (0.126-2.439) | 0.435 | |
Poorly-differentiated | NA | NA | NA | NA | |
Undifferentiated/anaplastic | 3.953 (1.35-11.567) | 0.012 | 0.702 (0.127-3.885) | 0.685 | |
Presence of PNI | 2.597 (1.845-3.656) | <0.001 | 1.470 (0.826-2.615) | 0.190 | |
Presence of LVI | 2.144 (1.504-3.055) | <0.001 | 1.754 (0.997-3.086) | 0.051 | |
Positive margin | 1.065 (0.148-7.680) | 0.950 | |||
Location Right-side colon | Reference | ||||
Left-side colon | 1.386 (0.778-2.472) | 0.268 | |||
Sigmoid colon | 1.281 (0.824-1.993) | 0.271 | |||
Upper rectum | 0.958 (0.464-1.979) | 0.907 | |||
Synchronous lesion | 1.535 (0.537-4.389) | 0.424 | |||
Adjuvant chemotherapy | 6.601 (3.969-10.980) | <0.001 | 5.485 (1.690-17.804) | 0.005 | |
A p-value<0.05 indicates statistical significance
Abbreviations: 95%CI, 95% confidence interval; aHR, adjusted hazard ratio; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; DFS, disease-free survival; DIT, diagnosis-to-surgery interval time; HR, hazard ratio; LVI, lymphovascular invasion; NA, not applicable/available; PNI, perineural invasion; p-value, probability value; T, tumor
TABLE 3. Multivariate analysis for independent predictors of decreased 3-year DFS in the DIT ≤30 days group.
Factors | HR (95%CI) | p-value | aHR (95%CI) | p-value | |
Age | 1.002 (0.981-1.023) | 0.872 | |||
Male sex | 1.061 (0.651-1.727) | 0.813 | |||
Body mass index | 0.974 (0.916-1.036) | 0.405 | |||
Charleson Comorbidity Index | 1.027 (0.903-1.168) | 0.683 | |||
ASA Class I | Reference | ||||
Class II | 1.212 (0.656-2.237) | 0.540 | |||
Class III | 1.831 (0.923-3.634) | 0.084 | |||
Preoperative CEA level >3.4 | 2.333 (1.327-4.103) | 0.003 | 2.146 (1.218-3.780) | 0.008 | |
Low preoperative albumin level | 0.701 (0.433-1.137) | 0.150 | |||
Laparoscopic surgery | 0.503 (0.520-1.378) | 0.503 | |||
Conversion | 2.197 (0.518-9.320) | 0.286 | |||
Depth of invasion T1 | Reference | ||||
T2 | NA | NA | |||
T3 | NA | NA | |||
T4 | NA | NA | |||
Lymph node metastasis | 2.411 (1.450-4.008) | 0.001 | 1.087 (0.607-1.946) | 0.779 | |
Lymph node harvested <12 nodes | 0.688 (0.276-1.714) | 0.422 | |||
Grade Well-differentiated | Reference | ||||
Moderately-differentiated | 1.514 (0.474-4.836) | 0.484 | |||
Poorly-differentiated Undifferentiated/anaplastic | NA 2.618 (0.625-10.955) | NA 0.188 | |||
Presence of PNI | 1.809 (1.102-2.971) | 0.019 | 1.143 (0.685-1.907) | 0.608 | |
Presence of LVI | 2.387 (1.438-3.962) | 0.001 | 1.707 (1.012-2.880) | 0.035 | |
Positive margin | 1.065 (0.148-7.680) | 0.950 | |||
Location Right-side colon | Reference | ||||
Left-side colon | 1.376 (0.580-3.266) | 0.469 | |||
Sigmoid colon | 1.636 (0.856-3.124) | 0.136 | |||
Upper rectum | 0.737 (0.208-2.610) | 0.636 | |||
Synchronous lesion | 2.161 (0.483-9.657) | 0.313 | |||
Adjuvant chemotherapy | 4.585 (2.268-9.269) | <0.001 | 3.825 (1.863-7.855) | <0.001 | |
A p-value<0.05 indicates statistical significance
Abbreviations: 95%CI, 95% confidence interval; aHR, adjusted hazard ratio; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; DFS, disease-free survival; DIT, diagnosis-to-surgery interval time; HR, hazard ratio; LVI, lymphovascular invasion; NA, not applicable/available; PNI, perineural invasion; p-value, probability value; T, tumor
TABLE 4. Multivariate analysis for independent predictors of decreased 3-year DFS in the DIT >30 days group.
Factors | HR (95%CI) | p-value | aHR (95%CI) | p-value | |
Age | 1.005 (0.986-1.025) | 0.595 | |||
Male sex | 0.841 (0.523-1.354) | 0.477 | |||
Body mass index | 0.978 (0.917-1.044) | 0.502 | |||
Charleson Comorbidity Index | 1.017 (0.902-1.146) | 0.787 | |||
ASA - Class I | Reference | ||||
- Class II | 0.947 (0.512-1.751) | 0.861 | |||
- Class III | 0.978 (0.486-1.967) | 0.950 | |||
Preoperative CEA level >3.4 | 2.105 (1.241-3.570) | 0.006 | 1.412 (0.822-2.424) | 0.211 | |
Low preoperative albumin level | 0.637 (0.423-0.958) | 0.030 | 0.611 (0.387-0.965) | 0.035 | |
Laparoscopic surgery | 0.594 (0.366-0.963) | 0.035 | 0.700 (0.425-1.152) | 0.161 | |
Conversion | 2.868 (0.858-9.521) | 0.087 | |||
Depth of invasion - T1 | Reference | ||||
- T2 | NA | NA | |||
- T3 | NA | NA | |||
- T4 | NA | NA | |||
Lymph node metastasis | 5.137 (3.001-8.795) | <0.001 | 1.789 (0.964-3.322) | 0.065 | |
Lymph node harvested <12 nodes | 1.644 (0.599-4.513) | 0.335 | |||
Grade - Well-differentiated | Reference | ||||
- Moderately-differentiated | 3.296 (0.806-13.478) | 0.097 | |||
| NA 6.224 (1.208-32.086) | NA 0.029 | |||
Presence of PNI | 3.788 (2.353-6.098) | <0.001 | 1.904 (1.160-3.124) | 0.011 | |
Presence of LVI | 1.925 (1.173-3.161) | 0.010 | 0.844 (0.494-1.441) | 0.534 | |
Positive margin | 2.071 (0.507-8.459) | 0.311 | |||
Location - Right-side colon | Reference | ||||
- Left-side colon | 1.413 (0.649-3.076) | 0.384 | |||
- Sigmoid colon | 1.007 (0.548-1.848) | 0.983 | |||
- Upper rectum | 1.064 (0.434-2.611) | 0.891 | |||
- Synchronous lesion | 1.121 (0.256-4.901) | 0.880 | |||
Adjuvant chemotherapy | 9.662 (4.623-20.194) | <0.001 | 5.444 (2.178-13.606) | <0.001 | |
A p-value<0.05 indicates statistical significance
Abbreviations: 95%CI, 95% confidence interval; aHR, adjusted hazard ratio; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; DFS, disease-free survival; DIT, diagnosis-to-surgery interval time; HR, hazard ratio; LVI, lymphovascular invasion; NA, not applicable/available; PNI, perineural invasion; p-value, probability value; T, tumor
extended delays of 3-6 months in colorectal cancer surgery could generate approximately 3,000 excess deaths annually, with significant reduction in quality-adjusted life-years.18 This temporal threshold of 3-6 months represents a duration substantially longer than our 30-day cutoff, supporting our hypothesis that brief delays may not compromise survival while extended deferrals pose significant oncological risks. The concordance between our empirical findings and these predictive models validates the concept that there exists a critical time threshold beyond which surgical delay becomes clinically detrimental, and that 30-day intervals fall below this threshold for non-metastatic colorectal carcinoma. Yung-Heng Lee et al. conducted a retrospective cohort study of 39,000 patients and found that delaying treatment for more than 30 days resulted in a lower 5-year OS rate. The study included patients with stage IV CRC who underwent surgery, chemotherapy, and radiation.12 Fabian Grass et al. conducted a study involving 118,504 patients who underwent elective surgery for colon cancer stage I-III and observed an increased mortality rate in the group of patients who delayed surgery for more than 40 days.13 In another retrospective cohort study by Maria Theresa Redaniel et al. involving 46,511 patients, a U-shaped relationship was observed between the time from diagnosis to surgery and 5-year OS. Patients who underwent surgery between 25-38 days had the highest survival rate, while those who delayed surgery for more than 38 days had a higher risk of death (HR 1.16; 95%CI 1.04-1.29), and those who had surgery less than 25 days had an even higher risk of death (HR 1.5; 95%CI 1.37-1.66).14 These findings suggest that a large population may be affected by the delay in treatment, leading to an
overpowered effect.
These findings have direct implications for surgical triage and hospital resource management. Although a short delay beyond 30 days may not adversely affect survival in low-risk patients, identifying high-risk individuals—such as those with nodal metastasis or hypoalbuminemia—can help prioritize surgical scheduling to minimize further delay. Implementation of a structured preoperative risk stratification model may facilitate optimal case allocation and enhance efficiency without compromising oncological outcomes. For instance, a recent study from our institution demonstrated that integrating histopathologic markers, such as lymphovascular invasion, with transcriptomic profiling can accurately predict lymph node metastasis19. Utilizing such predictive models could further refine preoperative triage and prioritize surgical scheduling for these high-risk patients. Furthermore, integrating these insights into national cancer care policies could support
the development of performance indicators that balance clinical urgency with real-world logistical constraints. Importantly, these clinical implications specifically apply to patients with colon and upper rectal cancer and should not be generalized to rectal cancer patients requiring neoadjuvant therapy, as their treatment paradigms and prognostic profiles are distinct.
Limitations
Study limitations include selection bias from retrospective design, limited sample size constraining statistical power, and unmeasured confounding variables affecting DIT associations. Exclusion of emergency presentations and middle/lower rectal cancers limits generalizability, as these populations have distinct prognostic profiles and treatment paradigms including neoadjuvant therapy. Specifically, contemporary approaches like total neoadjuvant therapy for locally advanced rectal cancer represent a separate clinical entity aimed at improving complete pathologic response rates and mitigating distant metastases.20 The cause of surgical delays was not documented, precluding identification of patient-, system-, or provider-related factors that could inform quality improvement initiatives. Furthermore, although a formal a priori power analysis was conducted to determine the target sample size, our final cohort comprised the entire eligible population available at our institution during the study period. Because this final number fell slightly short of the predetermined target, our statistical power to detect clinically meaningful differences in disease-free survival is restricted, risking a Type II error. This limited sample size also precludes definitive proof of causality in our subgroup analysis. Despite this limitation, our recommendation to prioritize patients with low albumin or lymph node metastasis is based on practical clinical principles; their inherently aggressive tumor biology and propensity for rapid progression strongly argue against any surgical delay. Prospective multicenter studies with larger cohorts, comprehensive covariate adjustment, and documentation of delay causation are needed to establish optimal DIT thresholds in non-metastatic CRC.
CONCLUSION
This retrospective cohort analysis demonstrated no significant association between diagnosis-to-surgery intervals exceeding 30 days and survival outcomes in non-metastatic colorectal cancer patients, though subgroup analysis revealed diminished disease-free survival among patients with nodal involvement and hypoalbuminemia experiencing delays. These findings suggest that short surgical delays beyond 30 days may be clinically acceptable
in selected low-risk patients; however, timely surgery remains paramount, particularly for vulnerable subgroups, and prospective studies are needed to validate optimal timing thresholds and inform clinical triage protocols.
All data used in this study is shown within the manuscript. However, any inquiries or requests for clarification about the data should be directed by the journal editor to the corresponding author.
ACKNOWLEDGEMENT
The authors gratefully acknowledge Sasima Tongsai for her assistance with statistical analysis.
DECLARATIONS
This was an unfunded study.
All authors hereby declare no personal or professional conflicts of interest relating to any aspect of this study.
None
Conceptualization and methodology, A.T, K.T. and
V.L. ; Investigation, A.T. and K.T. ; Formal analysis, A.T. and K.T. ; Visualization and writing – original draft, K.T. ; Writing – review and editing, A.T, K.T. ; Supervision,
A.T. All authors have read and agreed to the final version of the manuscript.
AI technology was not employed to develop any aspect of this study.
REFERENCES
Imsamran W, Pattatang A, Supaattagorn P, Chaiwiriyabunya I, Namthaisong K, Wongsena M, et al. Cancer in Thailand: Vol. IX, 2013-2015. Bangkok (Thailand): New Thammada Press; 2018. 186 p.
National Comprehensive Cancer Network. Colon Cancer (Version 4.2020) [Available from: https://www.nccn.org/ professionals/physician_gls/pdf/colon.pdf.
Zarcos-Pedrinaci I, Fernández-López A, Téllez T, Rivas-Ruiz F, Rueda A, Morales Suarez-Varela MM, et al. Factors that influence treatment delay in patients with colorectal cancer. Oncotarget. 2017;8(22):36728-42.
Lohsiriwat V, Chaisomboon N, Pattana-Arun J. Current Colorectal Cancer in Thailand. Ann Coloproctol. 2020;36(2): 78-82.
Helewa RM, Turner D, Park J, Wirtzfeld D, Czaykowski P, Hochman D, et al. Longer waiting times for patients undergoing colorectal cancer surgery are not associated with decreased survival. J Surg Oncol. 2013;108(6):378-84.
Flemming JA, Nanji S, Wei X, Webber C, Groome P, Booth CM. Association between the time to surgery and survival among patients with colon cancer: A population-based study. Eur J Surg Oncol. 2017;43(8):1447-55.
Wanis KN, Patel SVB, Brackstone M. Do Moderate Surgical Treatment Delays Influence Survival in Colon Cancer? Dis Colon Rectum. 2017;60(12):1241-9.
Hangaard Hansen C, Gogenur M, Tvilling Madsen M, Gogenur I. The effect of time from diagnosis to surgery on oncological outcomes in patients undergoing surgery for colon cancer: A systematic review. Eur J Surg Oncol. 2018;44(10):1479-85.
Bagaria SP, Heckman MG, Diehl NN, Parker A, Wasif N. Delay to Colectomy and Survival for Patients Diagnosed with Colon Cancer. J Invest Surg. 2019;32(4):350-7.
Lino-Silva LS, Guzman-Lopez JC, Zepeda-Najar C, Salcedo-Hernandez RA, Meneses-Garcia A. Overall survival of patients with colon cancer and a prolonged time to surgery. J Surg Oncol. 2019;119(4):503-9.
Trepanier M, Paradis T, Kouyoumdjian A, Dumitra T, Charlebois P, Stein BS, et al. The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients. J Gastrointest Surg. 2020;24(1):115-22.
Lee YH, Kung PT, Wang YH, Kuo WY, Kao SL, Tsai WC. Effect of length of time from diagnosis to treatment on colorectal cancer survival: A population-based study. PLoS One. 2019;14(1):e0210465.
Grass F, Behm KT, Duchalais E, Crippa J, Spears GM, Harmsen WS, et al. Impact of delay to surgery on survival in stage I-III colon cancer. Eur J Surg Oncol. 2020;46(3):455-61.
Redaniel MT, Martin RM, Blazeby JM, Wade J, Jeffreys M. The association of time between diagnosis and major resection with poorer colorectal cancer survival: a retrospective cohort study. BMC Cancer. 2014;14:642.
Roder D, Karapetis CS, Olver I, Keefe D, Padbury R, Moore J, et al. Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival. BMJ Open. 2019;9(9):e031421.
Kucejko RJ, Holleran TJ, Stein DE, Poggio JL. How Soon Should Patients With Colon Cancer Undergo Definitive Resection? Dis Colon Rectum. 2020;63(2):172-82.
Laird AK. Dynamics of tumor growth. Br J Cancer. 1964;13(3): 490–502.
Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020;31(8):1065–74.
Tangkullayanone W, Vorasan N, Chaiboonchoe A, Trakarnsanga A, Tanjak P, Suwatthanarak T, et al. Combining Histopathologic and Gene-Expression Profiling for Risk Stratification of Nodal Metastasis in Colorectal Cancer. Siriraj Med J. 2026;78(2):152-63.
Tawantanakorn T, Akaraviputh T, Chinswangwatanakul V, Ithimakin S, Petsuksiri J, Trakarnsanga A. Pathological and Oncologic Outcomes of Consolidation Chemotherapy in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiation. Siriraj Med J. 2023;75(4):282-9.